Brief: Acurx Says European Medicines Agency Granted SME Designation For Ibezapolstat EU Development
27/02/2024 12:53
Feb 27 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES FDA HAS GRANTED AN END OF PHASE 2 MEETING
FOR
IBEZAPOLSTAT FOR C. DIFFICILE INFECTION AND THE EUROPEAN
MEDICINES AGENCY GRANTED SME DESIGNATION FOR IBEZAPOLSTAT EU
DEVELOPMENT
* ACURX PHARMACEUTICALS INC: END OF PHASE 2 MEETING WITH FDA
IS
NOW CONFIRMED TO OCCUR IN LATE APRIL 2024 TO FINALIZE PHASE 3
DEVELOPMENT PLAN
Source text for Eikon: ID:nPn2PbMx3a
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program